ZBH:NYSE
Zimmer Biomet Holdings, Inc
$100.65
arrow_upward
+1.08%(+1.08) 1D
Aug 14, 4:00:04 PM GMT-4 · USD
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ZBH...
Open
$99.59
High
$101.16
Low
$98.97
Mkt. cap
19.20B
Avg. vol.
2.51M
Volume
0.00
Dividend
0.95%
Quarterly dividend
$0.24
Ex-dividend date
Jun 25, 2026
P/E ratio
24.50
52-wk high
$108.29
52-wk low
$79.12
EPS
$4.11
Beta
0.45
Shares outstanding
190.74M
No. of employees
17K
Open
$99.59
High
$101.16
Low
$98.97
Mkt. cap
19.20B
Avg. vol.
2.51M
Volume
0.00
Dividend
0.95%
Quarterly dividend
$0.24
Ex-dividend date
Jun 25, 2026
P/E ratio
24.50
52-wk high
$108.29
52-wk low
$79.12
EPS
$4.11
Beta
0.45
Shares outstanding
190.74M
No. of employees
17K
News stories
From web sources and news partners
MarketBeat
·
33 minutes ago
297,894 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by Alberta Investment Management Corp
Profile
Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
In 2001, Zimmer was spun off from Bristol Myers Squibb and began trading on the New York Stock Exchange, on August 7, under the ticker symbol “ZMH”. In November 2011, the company acquired ExtraOrtho, Inc. In January 2012, the company acquired Reno, Nevada-based Synvasive Technology, Inc. On June 29, 2015, the company changed the ticker symbol to "ZBH" to reflect its acquisition of Biomet.
On January 12, 2017, Zimmer Biomet announced a resolution with the DOJ and the SEC in which it agreed to pay a fine of approximately $30.5 million, an amount which would not affect its 2017 outlook. Wikipedia
About Zimmer Biomet Holdings, Inc
CEOIvan Tornos
Employees17K
Founded1927
HeadquartersWarsaw, Indiana, United States
SectorMedical device
Websitezimmerbiomet.com
Analyst ratings
Based on 17 analysts giving stock ratings to ZBH in the past 3 months
Buy
Buy
6
Hold
11
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for ZBH in the last 3 months.
Highest
Current $100.65
$120.00 (+19.23%)
Average
$105.29 (+4.61%)
Lowest
$93.00 (-7.60%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Joanne Wuensch Citi | Hold | Maintained | $99.00 | -1.6% | 08/13/2026 |
Travis Steed Bank of America Securities | Hold | Maintained | $110.00 | +9.3% | 08/11/2026 |
Richard Newitter Truist Financial | Hold | Maintained | $106.00 | +5.3% | 08/11/2026 |
Caitlin Roberts Canaccord Genuity | Buy | Maintained | $100.00 | -0.6% | 08/10/2026 |
Jeff Johnson Robert W. Baird | Hold | Maintained | $104.00 | +3.3% | 08/06/2026 |
Pito Chickering Deutsche Bank | Hold | Maintained | $98.00 | -2.6% | 08/06/2026 |
Steven Lichtman William Blair | Hold | Maintained | - | - | 08/06/2026 |
Patrick Wood UBS | Buy | Maintained | $120.00 | +19.2% | 08/06/2026 |
Lee Hambright Bernstein | Hold | Maintained | $93.00 | -7.6% | 08/06/2026 |
Rick Wise Stifel Nicolaus | Buy | Reiterated | $110.00 | +9.3% | 08/06/2026 |
Vik Chopra BMO Capital | Hold | Maintained | $96.00 | -4.6% | 08/06/2026 |
Larry Biegelsen Wells Fargo | Hold | Reiterated | $103.00 | +2.3% | 08/06/2026 |
Kendall Au RBC Capital | Buy | Reiterated | $110.00 | +9.3% | 08/05/2026 |
Michael Matson Needham | Hold | Maintained | - | - | 08/05/2026 |
Mathew Blackman TD Cowen | Buy | Maintained | $115.00 | +14.3% | 08/05/2026 |
Danielle Antalffy UBS | Buy | Upgraded | $115.00 | +14.3% | 07/28/2026 |
Ryan Zimmerman BTIG | Hold | Maintained | - | - | 07/23/2026 |
Shagun Singh Chadha RBC Capital | Buy | Maintained | $101.00 | +0.3% | 07/13/2026 |
Unknown Analyst BMO Capital | Hold | Initiated | $95.00 | -5.6% | 07/09/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $110.00 | +9.3% | 07/06/2026 |
Robbie Marcus J.P. Morgan | Hold | Maintained | $95.00 | -5.6% | 04/29/2026 |
Caitlin Cronin Canaccord Genuity | Hold | Reiterated | $83.00 | -17.5% | 04/29/2026 |
David Turkaly Citizens JMP | Buy | Maintained | $105.00 | +4.3% | 04/29/2026 |
Matt Miksic Barclays | Sell | Maintained | $94.00 | -6.6% | 04/29/2026 |
Mike Kratky Leerink Partners | Hold | Initiated | $101.00 | +0.3% | 04/13/2026 |
David Roman Goldman Sachs | Sell | Maintained | $88.00 | -12.6% | 02/10/2026 |
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$2.07 / $2.01
+2.99%beat
arrow_upward
Revenue / Est. (USD)
2.18B / 2.14B
+1.95%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 2.00B | 2.24B | 2.09B | 2.18B |
Cost of goods sold | 559.30M | 795.50M | 564.20M | 635.50M |
Cost of revenue | 559.30M | 795.50M | 564.20M | 635.50M |
Research and development expenses | 115.90M | 118.70M | 103.40M | 104.80M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 809.40M | 838.50M | 846.20M | 882.30M |
Operating expense | 1.10B | 1.13B | 1.11B | 1.15B |
Total operating expenses | 1.66B | 1.93B | 1.68B | 1.79B |
Operating income | 340.30M | 313.40M | 410.80M | 391.00M |
Other non operating income | 6.20M | 15.10M | 5.50M | 6.00M |
EBT including unusual items | 279.20M | 97.90M | 301.30M | 255.10M |
EBT excluding unusual items | 269.30M | 250.00M | 340.20M | 320.80M |
Income tax expense | 48.00M | -39.90M | 63.00M | 55.50M |
Effective tax rate | 17.19% | -40.76% | 20.91% | 21.76% |
Other operating expenses | - | - | - | - |
Net income | 230.90M | 139.30M | 238.10M | 198.30M |
Net profit margin | 11.54% | 6.21% | 11.41% | 9.11% |
Earnings per share | 1.90 | 2.42 | 2.09 | 2.07 |
Interest and investment income | - | - | - | - |
Interest expense | -75.40M | -71.90M | -68.80M | -72.90M |
Net interest expenses | -75.40M | -71.90M | -68.80M | -72.90M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 623.90M | 597.40M | 680.80M | 661.80M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
AI content may include mistakes. Learn more